Simona Scodes
Overview
Explore the profile of Simona Scodes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bronte G, Puccetti M, Petracci E, Landi L, Cravero P, Scodes S, et al.
Front Oncol
. 2021 May;
11:669839.
PMID: 34017688
Background: Current therapy for non-small-cell lung cancer (NSCLC) frequently includes immune checkpoint inhibitors, such as pembrolizumab, and programmed death ligand 1 (PD-L1) positivity is mandatory for its use in this...
2.
Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna G, Aerts J, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33077515
Background: The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless...
3.
Cortellini A, Friedlaender A, Banna G, Porzio G, Bersanelli M, Cappuzzo F, et al.
Clin Lung Cancer
. 2020 Jul;
21(6):498-508.e2.
PMID: 32680806
Background: The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab...
4.
Cortellini A, Tiseo M, Banna G, Cappuzzo F, Aerts J, Barbieri F, et al.
Cancer Immunol Immunother
. 2020 Jun;
69(11):2209-2221.
PMID: 32474768
Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. Methods: We conducted a multicenter...
5.
Scodes S, Cappuzzo F
Expert Rev Respir Med
. 2020 Apr;
14(6):565-576.
PMID: 32233809
: Epidermal growth factor receptor (EGFR) mutations occur in a significant fraction of non-small cell lung cancer (NSCLC) patients. Most common activating mutations are in-frame deletion in exon 19 and...